Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Toronto
$120,000.00
Prime Editing for the Therapeutic Correction of the Cystic Fibrosis G542X Mutation
EF 2025-26
Résumé
Cystic fibrosis (CF) is a life-threatening genetic disorder, where mutations in the CFTR gene cause a pathogenic thickening of mucus in the lungs. This thickening of mucus makes CF patients prone to frequent bacterial infections, which can ultimately cause potentially fatal respiratory failure. CF has a sizeable impact on Canadian health, being estimated to occur in 1 out of every 3800 live births, and is the most common fatal genetic disorder affecting young Canadians. While treatment options are available for some CF mutations, as of now none exist for the second most common CF-causing mutation (G542X), leaving a critically unmet medical need for several CF patients. This project aims to use the recently developed gene editing technology known as prime editing to permanently correct G542X, providing a curative treatment that directly addresses the root cause of the disease. Supporting this approach, our lab has developed best-in-class lipid nanoparticle (LNP) formulations that can safely deliver gene editing tools directly into the affected lung cells. Using lung cells carrying the G542X mutation, the prime editing machinery will be systematically optimized and specifically tailored to efficiently revert the G542X mutation to its functional non-pathogenic form. The therapeutic efficacy of this approach will then be further examined in a CF G542X mouse model to confirm its safety and potential for clinical translation. If successful, the treatment strategy proposed here would be a significant step forward for CF patients with unmet medical need and also provide a strong foundation for the treatment of many additional genetic disorders of the lung.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
559709
Name
Thomson Tyler A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Prime Editing for the Therapeutic Correction of the Cystic Fibrosis G542X Mutation
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Crispr; Cystic Fibrosis; Gene Editing; Gene Therapy; Lipid Nanoparticles; Lung Disease; Nucleic Acids; Prime Editing; Rna; Rna Therapeutics
Abstract
Cystic fibrosis (CF) is a life-threatening genetic disorder, where mutations in the CFTR gene cause a pathogenic thickening of mucus in the lungs. This thickening of mucus makes CF patients prone to frequent bacterial infections, which can ultimately cause potentially fatal respiratory failure. CF has a sizeable impact on Canadian health, being estimated to occur in 1 out of every 3800 live births, and is the most common fatal genetic disorder affecting young Canadians. While treatment options are available for some CF mutations, as of now none exist for the second most common CF-causing mutation (G542X), leaving a critically unmet medical need for several CF patients. This project aims to use the recently developed gene editing technology known as prime editing to permanently correct G542X, providing a curative treatment that directly addresses the root cause of the disease. Supporting this approach, our lab has developed best-in-class lipid nanoparticle (LNP) formulations that can safely deliver gene editing tools directly into the affected lung cells. Using lung cells carrying the G542X mutation, the prime editing machinery will be systematically optimized and specifically tailored to efficiently revert the G542X mutation to its functional non-pathogenic form. The therapeutic efficacy of this approach will then be further examined in a CF G542X mouse model to confirm its safety and potential for clinical translation. If successful, the treatment strategy proposed here would be a significant step forward for CF patients with unmet medical need and also provide a strong foundation for the treatment of many additional genetic disorders of the lung.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Thomson, Tyler A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~